{
  "docId": "019de073-742c-704c-a810-4500da4f1d81",
  "docSlug": "e78883ddf681fdb15564423388c7a078",
  "documentTitle": "Allarity Therapeutics | Investor Conference Presentation Deck | 23 slides",
  "authorId": "allarity-therapeutics",
  "authorName": "Allarity Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 23,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_messages",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Includes clinical efficacy data (PFS) and commercial context.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-742c-704c-a810-4500da4f1d81/16",
  "deckHref": "/decks/019de073-742c-704c-a810-4500da4f1d81",
  "deckJsonHref": "/decks/019de073-742c-704c-a810-4500da4f1d81.json",
  "deckAnchorHref": "/decks/019de073-742c-704c-a810-4500da4f1d81#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.6,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Progression Free Survival (months): Capecitabine 4.1 vs Ixempra + Capecitabine 5.7",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5cdd52a-c360-42d6-abe3-54d92d714e60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "Exclusively in-licensed for EU from R-PHARM U.S. Approved & marketed in U.S. for mBC. Ongoing Phase 2 trial in EU. R-PHARM providing drug supply and has buy-back option.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3b483d7-5195-4bd3-9ac2-64c027815225",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.85,
        "y": 0.55
      },
      "kind": "metric",
      "text": "Sales reached US$ 117m",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9b41a05-281e-46e5-8486-193ad66645f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "IXEMPRA® Approved in U.S. for 2nd Line Metastatic BC; Phase 2 Monotherapy Trial for mBC Ongoing in EU; Interim Data Readout Anticipated End of Q1 2023",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94a6174f-cd03-4813-ad65-fe998d8a7e17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "IXEMPRA® (Ixabepilone): A Microtubule Inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bab6485d-5518-4977-975c-e5c5dff23660",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "c2164b35-be59-4761-af95-cdd488be4a45",
      "evidence": "The slide features a list of bullet points highlighting the characteristics and benefits of IXEMPRA, including its approval status and ongoing Phase 2 trial.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b256bbaf-5ead-4fee-9327-1e3695ac93a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents DRP as a solution to the problem, highlighting its potential to personalize cancer care and improve patient outcomes.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}